Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

(2021) Mark A. Socinski et al.   Journal of Thoracic Oncology

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

(2020) G.R. Oxnard et al.   ANNALS OF ONCOLOGY

Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models

(2020) Qiaohong Wang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer

(2020) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance

(2020) Anna Passarelli et al.   Frontiers in Immunology

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

(2020) Benjamin C. Creelan et al.   BRITISH JOURNAL OF CANCER

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer

(2019) Tadaaki Yamada et al.   Cancer Medicine

EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: implications for combination therapies

(2019) Yijun Jia et al.   INTERNATIONAL JOURNAL OF CANCER

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

(2019) J Mazières et al.   ANNALS OF ONCOLOGY

Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma

(2019) Sun Min Lim et al.   LUNG CANCER

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

(2019) K Hastings et al.   ANNALS OF ONCOLOGY

Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC

(2018) Xue Li et al.   CANCER LETTERS

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

(2018) Hira Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab Plus Erlotinib in Patients With EGFR -Mutant Advanced NSCLC

(2018) Scott Gettinger et al.   Journal of Thoracic Oncology

Myeloid-derived suppressor cells coming of age

(2018) Filippo Veglia et al.   NATURE IMMUNOLOGY

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries

(2018) Hongmei Zeng et al.   Lancet Global Health

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma

(2018) Chee Khoon Lee et al.   JAMA Oncology

Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer

(2018) Si-yang Liu et al.   LUNG CANCER

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates

(2018) Yannick Simoni et al.   NATURE

Cytokines in clinical cancer immunotherapy

(2018) Pedro Berraondo et al.   BRITISH JOURNAL OF CANCER

Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without EGFR mutations

(2018) Eisaku Miyauchi et al.   CANCER SCIENCE

Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer

(2018) Satomi Watanabe et al.   CANCER SCIENCE

Does TMB Impact the Effectiveness of TKIs in EGFR-Mutant NSCLC?

(2018) Michael L. Cheng et al.   CLINICAL CANCER RESEARCH

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

(2017) Matthew A. Coelho et al.   IMMUNITY

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Dual Role of Treg in Cancer

(2017) M. Frydrychowicz et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent

(2017) Alice O. Kamphorst et al.   SCIENCE

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

(2017) Zhong-Yi Dong et al.   OncoImmunology

Cancer-derived extracellular vesicles: the ‘soil conditioner’ in breast cancer metastasis?

(2016) Andrew R. Chin et al.   CANCER AND METASTASIS REVIEWS

Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages

(2016) Don-Hong Wang et al.   CLINICAL CANCER RESEARCH

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

(2016) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Cell autonomous or systemic EGFR blockade alters the immune-environment in squamous cell carcinomas

(2016) Francesca Mascia et al.   INTERNATIONAL JOURNAL OF CANCER

Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3β/Foxp3 Axis

(2016) Sihua Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer

(2016) Elisabeth Brambilla et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types

(2016) Michael D. Iglesia et al.   JNCI-Journal of the National Cancer Institute

Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers

(2016) Aaron M. Chapman et al.   LUNG CANCER

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Exosome-Mediated Metastasis: From Epithelial–Mesenchymal Transition to Escape from Immunosurveillance

(2016) Nicholas Syn et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies

(2016) Charli Dominguez et al.   Cell Death & Disease

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

(2016) Jeffrey J. Wallin et al.   Nature Communications

EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models

(2016) Abhilash Venugopalan et al.   Oncotarget

AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells

(2016) Sherif Abdelhamed et al.   Journal of Cancer

Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types

(2016) Michael D. Iglesia et al.   JNCI-Journal of the National Cancer Institute

Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells

(2016) E. J. Brea et al.   Cancer Immunology Research

Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer

(2016) Jin S. Im et al.   PLoS One

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

(2015) C. Gebhardt et al.   CLINICAL CANCER RESEARCH

VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation

(2015) Hua Huang et al.   FASEB JOURNAL

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

(2015) Nan Chen et al.   Journal of Thoracic Oncology

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

(2015) Yanna Tang et al.   Oncotarget

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner

(2015) Rikke B. Holmgaard et al.   Cell Reports

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

(2014) K. Azuma et al.   ANNALS OF ONCOLOGY

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

The Role of Mechanical Forces in Tumor Growth and Therapy

(2014) Rakesh K. Jain et al.   Annual Review of Biomedical Engineering

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

(2014) A D'Incecco et al.   BRITISH JOURNAL OF CANCER

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma

(2014) Bicheng Zhang et al.   MEDICAL ONCOLOGY

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy

(2013) T Kumai et al.   BRITISH JOURNAL OF CANCER

Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients

(2013) Ang Huang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Epidermal Growth Factor Receptor-Containing Exosomes Induce Tumor-Specific Regulatory T Cells

(2013) Shao-hong Huang et al.   CANCER INVESTIGATION

Microenvironmental regulation of tumor progression and metastasis

(2013) Daniela F Quail et al.   NATURE MEDICINE

Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms

(2013) G Garrido et al.   ONCOGENE

Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1 surface expression

(2013) WANLU LU et al.   Oncology Letters

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Indoleamine 2,3-dioxygenase: From catalyst to signaling function

(2012) Francesca Fallarino et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

(2012) Y. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer

(2011) Marie Tosolini et al.   CANCER RESEARCH

Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes

(2011) B. P. Pollack et al.   CLINICAL CANCER RESEARCH

Amphiregulin Exosomes Increase Cancer Cell Invasion

(2011) James N. Higginbotham et al.   CURRENT BIOLOGY

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors

(2010) Myung Hee Chang et al.   CANCER

Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes

(2010) K. Movahedi et al.   CANCER RESEARCH

Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer

(2010) Kazuhiko Ino   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response

(2008) J.-Y. Wu et al.   CLINICAL CANCER RESEARCH

Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling

(2008) TacGhee Yi et al.   JOURNAL OF CELLULAR PHYSIOLOGY